BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 27, 2009
View Archived Issues
Reata Completes $32M Financing to Fund Studies of CKD Drug
Reata Pharmaceuticals Inc. has the cash to fund a mid-stage trial of its lead drug candidate for advanced chronic kidney disease, now that the Irving, Texas-based company has completed a $32 million Series F financing. (BioWorld Today)
Read More
Tricky Endpoints Doom Neurocrine Pain Trial
Read More
New Route for Toxic Asset's Exit Strategy is Discovered
Read More
Tackling Neurodegenerative Space, Neuraltus Raises $17M
Read More
Avigen Board Opts to Liquidate, Pending Shareholder Meeting
Read More
Other News To Note
Read More
Clinic Roundup
Read More